Karyopharm Therapeutics (KPTI) Research & Development (2012 - 2026)
Karyopharm Therapeutics (KPTI) reported Research & Development of $28.96 million for Q2 2026, down 11.7% from $32.79 million a year earlier.
Powered by 
Analysis
Karyopharm Therapeutics (KPTI) Research & Development (2012 - 2026) Analysis & Trends
Over the twelve months ended Jun 30, 2026, Karyopharm Therapeutics' Research & Development came in at $119.96 million, down 12.3% year-over-year; for FY2025, it was $125.62 million, down 12.3% from FY2024.
- Research & Development has a five-year compound annual growth rate of -3.6% (FY2020 to FY2025).
- By year, Research & Development came in at $143.23 million in FY2024 (+3.2%), $138.75 million in FY2023 (-6.7%), $148.66 million in FY2022 (-7.6%) and $160.84 million in FY2021 (+6.6%).
- Five-year quarterly Research & Development spans a low of $27.67 million in Q4 2025 and a high of $45.81 million in Q3 2021.
- Year over year, Research & Development gained in 1 of the last seven quarters, with an average decline of 10.7%.
- The high point for year-over-year Research & Development in five years was Q2 2022 (growth of 30.4%); the low point was Q3 2022 (a decline of 31.5%).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,136.97 Bn | 1,105.55 Bn | 19.71 Bn | 3.82 Bn |
| 2 | Johnson & Johnson | 619.72 Bn | 538.25 Bn | 17.26 Bn | 3.65 Bn |
| 3 | AbbVie | 503.40 Bn | 476.52 Bn | 12.70 Bn | 2.34 Bn |
| 4 | Merck | 370.15 Bn | 324.53 Bn | 12.21 Bn | 9.74 Bn |
| 5 | Novartis Ag | 298.64 Bn | 262.63 Bn | 11.24 Bn | 2.85 Bn |
| 6 | Astrazeneca | 261.07 Bn | 234.76 Bn | 12.86 Bn | 4.05 Bn |
| 7 | Amgen | 237.00 Bn | 192.40 Bn | 7.24 Bn | 1.87 Bn |
| 8 | Gilead Sciences | 191.24 Bn | 165.43 Bn | 6.22 Bn | 1.76 Bn |
| 9 | Pfizer | 170.31 Bn | 116.96 Bn | 10.94 Bn | 2.81 Bn |
| 10 | Karyopharm Therapeutics | 12.16 Mn | -214.27 Mn | 32.35 Mn | 28.96 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 28.96 Mn |
| Dec 31, 2025 | 27.67 Mn |
| Sep 30, 2025 | 30.54 Mn |
| Jun 30, 2025 | 32.79 Mn |
| Mar 31, 2025 | 34.62 Mn |
| Dec 31, 2024 | 33.30 Mn |
| Sep 30, 2024 | 36.13 Mn |
| Jun 30, 2024 | 38.37 Mn |
| Mar 31, 2024 | 35.43 Mn |
| Dec 31, 2023 | 39.38 Mn |
| Sep 30, 2023 | 35.55 Mn |
| Jun 30, 2023 | 31.48 Mn |
| Mar 31, 2023 | 32.34 Mn |
| Dec 31, 2022 | 30.93 Mn |
| Sep 30, 2022 | 31.36 Mn |
| Jun 30, 2022 | 44.31 Mn |
| Mar 31, 2022 | 42.06 Mn |
| Dec 31, 2021 | 44.00 Mn |
| Sep 30, 2021 | 45.81 Mn |
| Jun 30, 2021 | 33.98 Mn |
API Access
Karyopharm Therapeutics Research & Development API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=research-and-development&ticker=KPTI&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "research-and-development", "ticker": "KPTI", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=research-and-development&ticker=KPTI&period=max&api_key=YOUR_API_KEY");
const data = await res.json();